BioNTech SE (BNTX) FCF Margin (2018 - 2026)
BioNTech SE (BNTX) posted FCF Margin of 41.07% for Q4 2025, down 23.6% sequentially from 53.76% in Q3 2025, and up 4109.0% YoY from 0.98% in Q4 2024.
Powered by 
Analysis
BioNTech SE (BNTX) FCF Margin (2018 - 2026) Analysis & Trends
BioNTech SE has reported FCF Margin for 8 years, with the latest figure at 41.07% in Q4 2025.
- Quarterly FCF Margin rose 4109.0% year-over-year to 41.07% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 24.56% (up 2454.0% YoY) and the FY2025 annual result came in at 9.79%, up 1265.0% from the prior year.
- FCF Margin declined to 41.07% in Q4 2025 per BNTX's latest filing, from 53.76% in the prior quarter.
- Over five years, FCF Margin peaked at 2655.87% in Q2 2023 and troughed at 400.33% in Q1 2025.
- A 5-year average of 203.08% and a median of 33.59% in 2021 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin soared 253106 bps in 2023, then plunged 132270 bps in 2024.
- Over 5 years, FCF Margin stood at 4.32% in 2021, then soared by 423 bps to 22.57% in 2022, then surged by 180 bps to 63.2% in 2023, then tumbled by 100 bps to 0.01% in 2024, then jumped by 341774 bps to 41.07% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 41.07%, 53.76%, and 66.56% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | 61.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.65% |
| Mar 31, 2026 | -308.38% |
| Dec 31, 2025 | 41.07% |
| Sep 30, 2025 | 53.76% |
| Jun 30, 2025 | 66.56% |
| Mar 31, 2025 | -400.33% |
| Dec 31, 2024 | -33.34% |
| Sep 30, 2024 | -45.48% |
| Jun 30, 2024 | 1,333.18% |
| Mar 31, 2024 | -137.95% |
| Dec 31, 2023 | 63.20% |
| Sep 30, 2023 | 96.55% |
| Jun 30, 2023 | 2,655.87% |
| Mar 31, 2023 | -49.51% |
| Dec 31, 2022 | 22.57% |
| Sep 30, 2022 | 140.32% |
| Jun 30, 2022 | 124.81% |
| Mar 31, 2022 | 64.23% |
| Dec 31, 2021 | 4.32% |
| Sep 30, 2021 | 26.10% |